Dr. Greenblatt holds a dual doctorate, in microbiology and immunology from State University of New York, Downstate Medical Center, and is considered by many to be the foremost authority on polyvalent hyperimmune egg technology and its impact on the immune system. She has lectured extensively on the technology throughout the world, including the United States, Europe, Asia and Africa.

Dr. Hellen Greenblatt [Ph.D] is the Chief Science Officer of Legacy for Life, a direct sales company originally established as the marketing arm for DCV, Inc., a biotech company formed from a joint venture between DuPont and ConAgra to develop products that could benefit animal and human health.

Prior to joining Legacy for Life, Dr. Greenblatt was funded by the World Health Organization (WHO) and the National Institute of Health (NIH) for her studies on immune responses to infectious organisms. Dr. Greenblatt also received the highly competitive post-doctoral Research Council Associateship in Washington, D.C. under whose auspices she conducted studies in African sleeping sickness.

Dr. Greenblatt, or Dr. Hellen as she is affectionately known, has held research and management positions at premier scientific and medical companies. She was Vice President of Development for Clinical Sciences, Inc. (CSI) in NJ, where she developed highly specific tests [ELISAs] for detecting infection in mothers and their newborns. She is proud of the introduction of these tests into major hospitals and laboratory sites throughout the United States and around the globe.

After leaving CSI, Dr. Hellen became part of the HIV-assay development team at E. I. DuPont Nemours. In 1990 she left the group to become Founder and President of M-Cap Technologies International, a division of DuPont ConAgra Visions [a joint venture between DuPont and ConAgra]. Dr. Hellen also served as Vice President of the company when it became a separate entity [DCV Inc.] from DuPont and ConAgra. She established research programs for DCV Inc’s various science-oriented businesses, and helped design the quality assurance and quality control programs used to monitor the quality and uniformity of each batch of i²⁶ powder and Legacy for Life's i²⁶ COMPLETE support. Another of her primary responsibilities was the design of protocols for pre-clinical and clinical trials. Their results validated the structure and function claims made about i²⁶.

A member of the New York Academy of Sciences, American Academy of Anti-Aging Medicine, and the American Society for Nutrition, Dr. Hellen is widely published and holds patents and applications for polyvalent hyperimmune egg, including pivotal gastrointestinal health patents.

Among a few select individuals, Dr. Hellen has been cited in many biographical references including...
Who's Who in America 62nd Edition 2008
Who's Who of American Women, 2006-2007 25th Sliver Anniversary Edition
Who’s Who in Medicine and Healthcare 2006-2007
2005 Woman of Achievement Award
International Scientist of the Year-2004
American Men and Women of Science (21st Edition) (The premier biographical reference on North American Scientists)